Author(s): Gokul Prabhakaran and Rajbir Bakshi
Objective: The purpose of this analysis is to understand the structure and change in costs for an established longitudinal study of Alzheimer’s disease with fixed enrollment.
Methods: The examination begins with a discussion of the design of the consortium based study and the types of data collected by the researchers. Financial statements (2005 to 2017) are analyzed and forward projections are confirmed using linear regression. Funding is broken down by institution, with looks at per patient and personnel costs.
Results: The rate of change for the costs is highly variable but correlated between institutions. Personnel costs are a critical driving factor. Per patient costs are noted to vary significantly between research institutions. The experiment will not be able to continue in its present form unless costs are brought to equilibrium with available funding. Sources of funding will need to consider opportunity costs, growth rates, and concurrent obligations as they evaluate projects.
Conclusion: The longitudinal study is currently the most effective study design for progressive diseases. Funding for research does not align with the demonstrated need.
